ENDPOINTS NEWS9m
No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M
Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic ...
ENDPOINTS NEWS2h
Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?
Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...
ENDPOINTS NEWS1h
Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...
ENDPOINTS NEWS1h
Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds
San Diego biotech Aven­zo Ther­a­peu­tics has in-li­censed an­oth­er as­set, this time se­cur­ing the glob­al ex-Chi­na ...
ENDPOINTS NEWS1h
Cy­bin says its psy­che­del­ic drug can sus­tain re­mis­sion in de­pres­sion pa­tients
Cy­bin said its psilocin ana­log has the po­ten­tial to wipe out symp­toms in most pa­tients with a se­ri­ous form of ...
ENDPOINTS NEWS6h
Ex­clu­sive: Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...
ENDPOINTS NEWS4h
In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set
In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...
ENDPOINTS NEWS1d
Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges
Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...
ENDPOINTS NEWS2d
Trump picks RFK Jr. for HHS; Ab­b­Vie's psych im­plo­sion; Mer­ck tries staving off Sum­mit; and more
AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...
ENDPOINTS NEWS2d
Il­lu­mi­na seeks to dis­miss share­hold­er law­suit, de­nies se­cret $800M stake
Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...
ENDPOINTS NEWS2d
Eu­ro­pean drug reg­u­la­tors of­fer wave of pos­i­tive rec­om­men­da­tions fol­low­ing Leqem­bi re­ver­sal
EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...
ENDPOINTS NEWS2d
Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy
Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...